
Fuite para prothétique mitrale Quelles techniques?











DÉCLARATION DE LIENS D'INTÉRÊT AVEC LA PRÉSENTATION

Intervenant: Didier CHAMPAGNAC, Villeurbanne

☑ Je déclare les liens d'intérêt suivants :

Honoraires : ABBOTT

Qu'est-ce qu'une fuite sévère?

Paramètres écho

3-Class Grading Scheme	Trace	Mild		Moderate		Severe	
4-Class Grading Scheme	1	1	2	2	3	4 Severe	
Unifying 5-Class Grading Scheme	Trace	Mild	Mild-to-Moderate	Moderate	Moderate to Severe		
Doppler echocardiography							
Structural parameters							
Sewing ring motion*	Usually normal	Usually normal	Normal/abnormal†	Normal/abnormal†	Normal/abnormal†	Normal/abnormal†	
LA and LV size‡§	Normal	Normal	Normal	Normal/mildly dilated	Mildly/moderately dilated	Moderately/severely dilated	
RV size and function‡§	Normal	Normal	Normal	Normal/mildly dilated	Mildly/moderately dilated	Moderately/severely dilated	
Estimation of pulmonary artery pressures‡	Normal	Normal	Normal	Variable	Increased	Increased (TR velocity >3 m/s, SPAP ≥50 mm Hg at rest and ≥50 mm Hg with exercise)	

PVL, % (color Doppler)*						
Doppler parameters (quantitat	ive)					
RVol, ml/beat‡**	<10	<15	15 to <30	30 to <45	45 to <60	
RF, %‡	<15	<15	15 to <30	30 to <40	40 to <50	
EROA, mm ² ࠠ	<5	<5	5 to <20	20 to <30	30 to <40	
CMR imaging						
Regurgitant fraction, %##	<15	<15	15 to <30	30 to <40	40 to <50	\

*Parameters that are most frequently used to grade regurgitation severity by Doppler echocardiography. †>15° of sewing ring motion that is not consistent with normal phasic that are less often applicable due to pitfalls in the feasibility/accuracy of the measurements or to the interaction with other factors. §For bileaflet mechanical valve, 1.9 m/s

+ clinique:

Hémolyse

> Insuff.card.

Doppler parameters (qualitative	e or semiquantitative	2)				
Proximal flow convergence visible*	Absent	Absent/minimal	Absent/minimal	Intermediate	Intermediate	Large
Color Doppler jet area (Nyquist 50-60 cm/s)‡	Absent	Small, central jet (usually <4 cm ² or <20% of LA area)	Small, central jet (usually <4 cm ² or <20% of LA area)	Variable	Variable	Large central jet (usually >8 cm ² or >40% of LA area) or variable when wall impinging
Mean gradient (CW)‡	Normal	Normal	Normal	Increased	Increased	≥5 mm Hg
CT UCTYL (CW)#	Normal (<130 ms)	Normal (<130 ms)	Normal (<130 ms)	Normal (<130 ms)	Normal (<130 ms)	Normal (<130 ms)
Jet profile (Not measurable	<2	2 to <3	3 to <5	5 to <7	osystolic/tria
· \\	Incomplete or faint	Incomplete or faint	Variable	Dense	Dense /	`
	Parabolic	Parabolic	Variable (partial or parabolic)	Variable (partial or parabolic)	Variable (partial parabolic)	
Pulmonary veii	Systolic dominance	Systolic dominance	Systolic dominance	Systolic blunting	Systolic bluntin yS	tolic flow revers
(PW Dop	Equal (1:1)	Slightly increased	Slightly increased	Intermediate	Intermediate	
MV _{PR} flow:LV	Not quantifiable	<5	5 to <10	10 to <20	20 to <30	≥2.5
(PW (quantitati	ive)					
Rvoi, mt/beat‡**	<10	<15	15 to <30	30 to <45	45 to <60	≥60

≥60

≥50

≥40

≥50

Par où on passe? Avec quel matériel?

TSP vs trans apicale.


Si TSP, franchissement antérograde ou rétrograde?

Si rétrograde, trans aortique sauf si RVA méca.
 (et encore...)

Quel matériel?


- TSP « habituel » et bistouri électrique si pas bayliss
- AGILIS
- Guide TERUMO droit, 150, 180, 260 cm
- JR4 ou autre...
- Guide Stiff (celui des TAVI par ex)
- Intro COOK ou TERUMO 5, 6 et 7 French, 90 ou 100 cm
- Gooseneck (Medtronic) ou En snare (Merit Medical)
- Matériel chir si T.A (repérage ETT apex) Pas d'expérience de voie percutanée apicale.
- Les « dispositifs »: AVP (2, 3 et 4), VSD, ADO 2 ...+ occlutech

Devices for mitral PVL



Waist & Twist

The Occlutech PLD is available with two types of connections between the discs, **W**aist or **T**wist. Example below shown on a Occlutech PLD Square.











Figure 1. Shape of paravalvular leaks. Paravalvular leaks can take a variety of shapes. These include round (A), oval (B), slit-like (C) and crescentic (D).








Cas « facile »: fuite bien décrite, site accessible en TSP

- Patient né en 1957
- RVA + RVM méca 2011
- Hémolyse et insuffisance cardiaque 2017
- ETT: ITV mitrale/Ao = 2.5, HTAP 65 mm Hhg
- ETO: PVL située entre 8 et 9 heures, ovale,
 12mm/4mm
- Plan: voie antérograde, Plug AVP3











THE THRILL LUID

Evolution


Favorable, disparition de l'hémolyse, NYHA 2


Rapport procédure:


- > scopie: 24 min.
- Air Kerma: 418 mGy
- ➤ PDS: 4325 microGy.m2


Cas plus compliqué, 2 fuites


- Patiente , 1946.,1.55 m, 78 Kg
- ATCD ADK sein G: radio/chimio
- Oct. 2016: RVM mécanique
- Mars 2017: DE stade 3, Hb 9.7 g/l, LDH 350
- 2 fuites, la plus importante latérale, l'autre médiale.
- Plan: Voie TSP, fuite latérale N1, AVP3 12 mm




































Evolution


- Pas d'hémolyse
- D.E stade 2
- Rapport procédure:
- > Scopie: 19 min
- > Air Kerma: 235 mGy
- ➤ PDS: 3685 microGy.m2


Un échec. Quelle raison?


- Patiente 75 ans
- Commissurotomie sous CEC 1975, RVM méca.1994, hémolyse/FPV et chir tridux en janv 2016: RVM bio.
- Sepsis, El, désinsertion et FPV sévère.
- Hémolyse +++ et insuff.cardiaque, sepsis « guéri »
- ETT, ETO: fuite grade 3, HTAP 80 mm Hg, bon VG













évolution


- Hémolyse persistante, sévère.
- Transfusions bimensuelles....
- Reprise chirurgicale 19/01/2017, 4^{ième} CEC
- Euroscore 2: 47%
- 3 points tressés sur attelle de téflon, clampage 53 min, CEC 71 min
- Suivi: bonne évolution clinique, disparition de la fuite, guérison de l'hémolyse.


Une conversion TSP/TA

- Patient né en 1959
- Hodgkin radiothérapé à 20 ans
- RVA bio en 2003
- RVM bio en mars 2016
- Evolution défavorable: insuffisance cardiaque gauche, FA et thrombus de l'auricule.
- découverte de Fuite paraprothétique mitrale
- Plan: F.A.G et fermeture paraP.











F#123


Dist 0.628 cm Dist 0.315 cm


Délai 0ms


50bpm














Conclusions (1)

- Voie antérograde par TSP le plus souvent possible
- Si on fait « un rail », recouvrir le guide avec une sonde 4 ou 5 Fr
- Accès transeptal : POST et plus ou moins SUP selon le siège de la fuite
- ANTICIPER les cas difficiles (situation, trajet, calcifications)
- ANTICIPER le risque d'interférence avec les ailettes (valve monodisque, trajet oblique, large fuite...) et le choix du dispositif

Conclusions (2)

- Pas de technique « miracle »
- Faire ce que l'on pratique le plus souvent, mais essor de la voie transeptale.
- Matériel « d'approche » correct mais <u>dispositifs</u> trop imparfaits, non dédiés (hors Occlutech)
- Balance à trouver entre taille des gaines d'accès et taille des dispositifs
- Essayer d'être le plus complet possible en une fois
- Succès technique: 75/85%, succès clinique: 65/75%



MERCI DE VOTRE ATTENTION



Outcomes and predictors of success and complications for paravalvular leak closure: an analysis of the SpanisH real-wOrld paravalvular LEaks closure (HOLE) registry

Eulogio García¹, MD; Dabit Arzamendi², MD, PhD; Pilar Jimenez-Quevedo³, MD, PhD; Fernando Sarnago⁴, MD; Gerard Martí⁵, MD; Angel Sanchez-Recalde⁶, MD; Garikoit Lasa-Larraya⁷, MD; Manuel Sancho⁸, MD, PhD; Andres Iñiguez⁹, MD, PhD; Javier Goicolea¹⁰, MD; Koldobika García-San Roman¹¹, MD; Juan Horacio Alonso-Briales¹², MD; Eduardo Molina¹³, MD; Jose Calabuig¹⁴, MD; Xavier Freixa¹⁵, MD; Alberto Berenguer¹⁶, MD, FESC; Mariano Valdes-Chavarri¹⁷, MD, PhD; Nicolas Vazquez¹⁸, MD; Jose Francisco Diaz¹⁹, MD; **Ignacio Cruz-Gonzalez^{20*}**, MD, PhD

1. Hospitales Universitarios Montepríncipe and Moncloa, Madrid, Spain; 2. Hospital Santa Creu y San Pau, Barcelona, Spain; 3. Hospital Clínico San Carlos, Madrid, Spain; 4. Hospital Gregorio Marañón, Madrid, Spain; 5. Hospital Vall D'Hebron, Barcelona, Spain; 6. Hospital la Paz, Madrid, Spain; 7. Hospital Universitario Donostia, San Sebastian, Spain; 8. Hospital Puerta del Mar, Cadiz, Spain; 9. Hospital Meixoeiro, Vigo, Spain; 10. Hospital Puerta de Hierro, Madrid, Spain; 11. Hospital Universitario de Cruces, Baracaldo, Spain; 12. Hospital Virgen de la Victoria, Malaga, Spain; 13. Complejo Hospitalario Universitario de Granada, Granada, Spain; 14. Clínica Universitaria de Navarra, Pamplona, Spain; 15. Hospital Clínic de Barcelona, Barcelona, Spain; 16. Hospital General Universitario Valencia, Valencia, Spain; 17. Hospital Virgen de la Arrixaca, Murcia, Spain; 18. Hospital Universitario da A Coruña, A Coruña, Spain; 19. Hospital Juan Ramón Jiménez, Huelva, Spain; 20. Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain

This paper also includes supplementary data published online at: http://www.pcronline.com/eurointervention/113th_issue/320

Abstract

Aims: The aim of the study was to assess the safety and efficacy of percutaneous closure of paravalvular prosthetic leak (PVL) and to identify the predictors of procedural success and early complications.

Methods and results: A total of 514 first-attempt percutaneous PVL closure in 469 patients were included at 19 centres. Technical and procedural success was achieved in 86.6% and 73.2% of the patients, respectively. In multivariate analysis, the independent predictors for procedural success in mitral lesions were the type of device used (AMPLATZER AVP III vs. others, HR 2.68 [1.29-5.54], p=0.008) and the number of procedures performed at the centre (top quartile vs. others, HR 1.93 [1.051-3.53], p=0.03). For aortic leaks the only predictor of procedural success was the leak size (≥10 mm vs. <10 mm, HR 3.077 [1.13-8.33], p=0.027). The overall major adverse events rate (death or emergency surgery or stroke) at 30 days was 5.6%; the only predictor for combined adverse events was New York Heart Association functional Class IV (HR 4.2 [1.42-12.34], p=0.009).

Conclusions: Percuta sus closure of PVL can be performed with a reasonable rate of procedural success and a low rate of major complications. The type of device used, the accumulated experience and the leak size are predictors of procedural success.

2/3 PVL Mitrales, plus de 90% par transeptal et souvent franchissement rétrograde

Fuite paraprothétique mitrale Quelles techniques?

DEFINIR et ANALYSER

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

© 2017 AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

AND EUROPEAN SOCIETY OF CARDIOLOGY.

VOL. 69, NO. 16, 2017 ISSN 0735-1097/\$36.00 http://dx.doi.org/10.1016/j.jacc.2017.02.038

THE PRESENT AND FUTURE

PVLARC Committe

STATE-OF-THE-ART REVIEW

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis



An Expert Statement


Carlos E. Ruiz, MD, PhD,^a Rebecca T. Hahn, MD,^b Alain Berrebi, MD,^c Jeffrey S. Borer, MD,^d Donald E. Cutlip, MD,^e Greg Fontana, MD,^f Gino Gerosa, MD,^g Reda Ibrahim, MD,^h Vladimir Jelnin, MD,^a Hasan Jilaihawi, MD,ⁱ E. Marc Jolicoeur, MD,^h Chad Kliger, MD,^j Itzhak Kronzon, MD,^j Jonathon Leipsic, MD,^k Francesco Maisano, MD,^l Xavier Millan, MD,^m Patrick Nataf, MD,ⁿ Patrick T. O'Gara, MD,^o Philippe Pibarot, DVM,^p Stephen R. Ramee, MD,^q Charanjit S. Rihal, MD,^r Josep Rodes-Cabau, MD,^p Paul Sorajja, MD,^s Rakesh Suri, MD,^t Julie A. Swain, MD,^u Zoltan G. Turi, MD,^v E. Murat Tuzcu, MD,^t Neil J. Weissman, MD,^w Jose L. Zamorano, MD,^x Patrick W. Serruys, MD, PhD,^y Martin B. Leon, MD,^b of the Paravalvular Leak Academic Research Consortium


Fuite étendue? à fermer en une fois!

- Patient né en 1957
- 1979: RVA mécanique, et RVM bio
- 1988: RVM mécanique
- 2009: RVM (mécanique) redux pour désinsertion
- MCI: angioplasties multiples
- FA permanente
- Anémie hémolytique et insuffisance cardiaque

analyse

- Désinsertion importante, étendue sur 20 mm; postéro-latérale
- « Largeur » 4 mm
- Retentissement hémodynamique
- Décision fermeture percutanée
- Certainement au moins 2 dispositifs





Evolution

- Bonne efficacité sur l'hémolyse
- Mais persistance de signes d'insuffisance cardiaque
- Décision de reprise pour complément, fuite autour du dispositif précédent

